Benvitimod

Clinically meaningful improvements in sleep scores, as measured by subdomains of the Patient-Oriented Eczema Measure (POEM) and Dermatitis Family Impact (DFI) assessments, were observed as early as week 1 and continued through week 8 JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present results from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating VTAMA cream versus vehicle at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, Pennsylvania, on February 27, 2026. The findings show that VTAMA cream provided early and consistent improvements in the POEM sleep subdomain for pediatric patients down to age 2 with moderate to severe atopic dermatitis (AD) and in the DFI sleep subdomain for family members of patients aged 2-15 years. “Sleep disturbance is a significant problem for children with atopic dermatitis and their families, and one that I always take time to address in my clinic,” said Dr. Mark Boguniewicz, Professor in the Department of Pediatrics, Division of Allergy and Immunology at National Jewish Health and the University of Colorado School of Medicine, and an author of the analysis being presented at the AAAAI meeting. “When a child with atopic dermatitis struggles through the night, parents and caregivers are often awake as well, sharing in the fatigue and emotional stress associated with ongoing sleep disturbance.” In the ADORING 1 and ADORING 2 pivotal trials, adults and children (≥2 years; N=813) with moderate to severe AD were randomized 2:1 to VTAMA cream or vehicle once daily for 8 weeks. These findings presented at AAAAI 2026 come from a sub‑analysis of pooled data from 654 children aged 2 to 17 years enrolled in ADORING 1 and ADORING 2. Clinically relevant improvements in sleep subdomains of patient-reported outcomes, as measured by POEM and DFI scores, were seen across all age groups, including pediatric patients down to age 2 with moderate to severe AD and family members of patients aged 2-15 years. Notable findings include 1 : Mean POEM sleep subdomain scores significantly improved as early as week 1 with VTAMA cream versus vehicle for children aged 2-6 and 12-17, with improvements in children aged 7-11 observed by week 4. Mean changes in POEM sleep scores with VTAMA cream versus vehicle at week 8 were clinically significant across age groups: -1.9 vs. -0.9 for children aged 2-6 ( P <0.0001), -1.5 vs. -1.0 for children aged 7-11 ( P =0.0029), and -1.2 vs. -0.6 for children aged 12-17 ( P <0.0001). Mean DFI sleep subdomain scores significantly improved as early as week 1 with VTAMA cream versus vehicle in patients aged 12-15 and as early as week 2 for children aged 2-6 and 7-11. Clinically significant improvements in DFI sleep subdomain scores continued through week 8 with VTAMA cream versus vehicle: -1.1 vs. -0.6 for children aged 2-6 ( P =0.0002), -0.6 vs. -0.4 for children aged 7-11 ( P =0.0049), and -0.4 vs. -0.2 for children aged 12-15 ( P =0.0283). Consistent with the prescribing information, the most frequently reported (≥5% in any group) treatment-emergent adverse events in the ADORING 1 and ADORING 2 clinical trials were folliculitis, headache, and nasopharyngitis. “These findings demonstrate early and sustained improvements in sleep-related measures, including for those as young as two years of age,” said Juan Camilo Arjona Ferreira, MD, Head of R&D and Chief Medical Officer at Organon. “Sleep disturbance is an important and measurable aspect of pediatric atopic dermatitis, and these positive results reinforce our commitment to advancing therapies that address meaningful treatment outcomes across chronic skin conditions. We are encouraged by these findings and look forward to continuing to disseminate data that are clinically relevant for patients, caregivers, and prescribers.” In December 2024, the US Food and Drug Administration (FDA) approved VTAMA cream for the topical treatment of AD in adults and pediatric patients 2 years of age and older. VTAMA cream was also approved by the FDA in May 2022 for the topical treatment of plaque psoriasis in adults. About the Phase 3 Program for VTAMA cream in Atopic Dermatitis ADORING was the Phase 3 AD clinical development program for VTAMA cream, consisting of two 8-week pivotal trials, ADORING 1 (NCT05014568) and ADORING 2 (NCT05032859), as well as ADORING 3 (NCT05142774), a 48-week, open-label, long-term extension trial. INDICATIONS: VTAMA ® (tapinarof) cream, 1% is an aryl hydrocarbon receptor (AhR) agonist indicated for: the topical treatment of plaque psoriasis in adults the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older SELECTED SAFETY INFORMATION Adverse Events: In plaque psoriasis, the most common adverse reactions (incidence ≥1%) were: folliculitis, nasopharyngitis, contact dermatitis, headache, pruritus, and influenza. Adverse Events: In atopic dermatitis, the most common adverse reactions (incidence ≥1%) were: upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and abdominal pain. Before prescribing VTAMA cream, please read the Prescribing Information . For more information about VTAMA (tapinarof) cream, 1%, visit About Atopic Dermatitis (AD) AD, commonly referred to as eczema, is one of the most prevalent inflammatory skin diseases, affecting an estimated 26 million people in the U.S. alone and up to 10% of adults worldwide. 2,3 AD occurs most frequently in children, affecting up to 20% worldwide, including nearly 10 million children in the U.S. 3,4 The disease results in itchy, red, swollen, and cracked skin, often on the folds of the arms, back of the knees, hands, face, and neck. 2 Itching is an especially bothersome symptom for those with AD, and tends to worsen at night. 3 About Organon Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately, or differently affect women, while expanding access to essential treatments in over 140 markets. Headquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare. Learn more at and follow us on LinkedIn , Instagram , X , YouTube , TikTok , and Facebook . Cautionary Note Regarding Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about Organon’s intent to present results about VTAMA as a treatment option for AD and continuing to disseminate clinically relevant data about VTAMA. Forward-looking statements may be identified by words such as “will,” and “look forward to” or words of similar meaning. These statements are based upon the current beliefs and expectations of Organon’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause results to differ materially from those described in the forward-looking statements can be found in Organon’s filings with the SEC, including Organon’s most recent Annual Report on Form 10-K and other SEC filings, available at the SEC’s Internet site ( ). Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. © 2026 Organon group of companies. All rights reserved. US-VTA-113179 02/26 1 Boguniewicz M, Eichenfield LF, Kwong P, Hebert AA. Improvement in sleep and family impact for pediatric patients down to two years of age with atopic dermatitis treated with tapinarof cream 1% once daily in two pivotal phase 3 trials. Poster presented at: American Academy of Allergy, Asthma and Immunology Annual Meeting; February 27 - March 2, 2026; Philadelphia, PA. 2 Atopic dermatitis. National Institute of Arthritis and Musculoskeletal and Skin Diseases. November 2022. Accessed August 19, 2025. . 3 Eczema stats. National Eczema Association. Accessed June 5, 2025. . 4 Global Report on Atopic Dermatitis 2022. International League of Dermatological Societies; 2022. Accessed February 25, 2025. . Contacts Media: Felicia Bisaro (646) 703-1807 Investor: Jennifer Halchak (201) 275-2711

氨基观察-创新药组原创出品 作者 | 黄恺 艾加莫德卖爆了。 2月26日，Argenx 发布2025年财报，全年营收42.48亿美元，归母净利润为 12.92 亿美元，首次实现盈利。 Argenx仅有一款商业化产品，即艾加莫德，2025年销售额为41.51亿美元，同比增长90%。 2026年开年，互联网诊疗监管力度持续加码。 截止目前，全国已有北京、天津、湖南、福建、上海、江西等多个省市通过地方性法规或政策文件，对AI自动生成处方亮起“红灯”。 诺和诺德继续布局新技术。 2月25日，诺和诺德宣布与Vivtex达成合作协议，开发用于治疗肥胖、糖尿病及相关合并症的下一代口服生物制剂。根据协议，Vivtex将向诺和诺德授权部分口服药物递送技术，而Vivtex则有资格获得最高21亿美元的预付款、研究资金和里程碑付款，以及未来产品销售额的分级版税。 在过去的一天里，国内外医药市场还有哪些热点值得关注？让氨基君带你一探究竟。 / 01 / 市场速递 1）济川药业获得本维莫德乳膏商业化权益 2月26日，济川药业公告称，全资子公司济川有限与泽德曼签署独占性商业化权益协议，泽德曼授权济川有限在合作期限内独家负责其拥有的泽立美®本维莫德乳膏在中国大陆地区（不包含香港、澳门和台湾地区）的商业化。济川有限支付的首付款及里程碑付款将不超过1.9亿元（含税）。 2）严禁AI自动开方审方，多地陆续“亮红灯” 2026年开年，互联网诊疗监管力度持续加码。全国已有北京、天津、湖南、福建、上海、江西等多个省市通过地方性法规或政策文件，对AI自动生成处方亮起“红灯”。 / 02 / 资本信息 1）百奥赛图2025年营收预计增长40.63% 2月26日，百奥赛图发布2025年业绩预告。报告期内，公司预计营业收入为人民币13.79亿元，较去年同期预计增长40.63%；归属于母公司所有者的净利润预计为人民币1.73亿元，较去年同期预计增长416.37%。 2）新诺威拟2.3亿元转让国新汇金30%股份给石药控股 2月26日，新诺威公告称，公司拟将持有的国新汇金30.0704%股份以2.3亿元价格转让给石药控股，转让完成后，公司将不再持有国新汇金股份。 3）康希诺2025年净利润2787.27万元 2月26日，康希诺公告，2025年度实现营业总收入10.68亿元，同比增长26.18%；归母净利润2787.27万元，上年同期亏损3.79亿元。 4）智翔金泰2025年亏损5.29亿元 2月26日，智翔金泰发布2025年业绩快报，全年营业总收入约为人民币2.31亿元，较去年同期增长666.65%；营业利润约为亏损人民币5.29亿元，较去年同期下降33.57%。 / 03 / 医药动态 1）诺诚健华BCL2抑制剂联合奥布替尼3期临床完成患者入组 2月26日，诺诚健华宣布，公司自主研发的新型BCL2抑制剂mesutoclax（ICP-248） 联合BTK抑制剂奥布替尼一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）的注册性3期临床试验已经完成患者入组。 / 04 / 海外药闻 1）21亿美元！诺和诺德引进生物药口服递送技术 2月25日，诺和诺德宣布与Vivtex达成合作协议，开发用于治疗肥胖、糖尿病及相关合并症的下一代口服生物制剂。根据协议，Vivtex将向诺和诺德授权部分口服药物递送技术，而Vivtex则有资格获得最高21亿美元的预付款、研究资金和里程碑付款，以及未来产品销售额的分级版税。 2）礼来RET激酶抑制剂3期研究取得积极结果 2月26日，礼来公司宣布，LIBRETTO‑432 3期临床研究取得阳性顶线结果。该研究评估了塞普替尼作为辅助治疗相较于安慰剂的有效性和安全性。研究达到了其主要终点，证实在研究者评估的早期（II-IIIA期）转染重排（RET）融合阳性非小细胞肺癌患者中，塞普替尼带来了高度统计学显著且具有临床意义的无事件生存期改善。 3）艾加莫德大卖42亿美元 2月26日，Argenx 发布2025年财报，全年营收42.48亿美元，归母净利润为 12.92 亿美元，首次实现盈利。Argenx仅有一款商业化产品，即艾加莫德，2025年销售额为41.51亿美元，同比增长90%。 PS：欢迎扫描下方二维码，添加氨基君微信号交流。